(R)-2-mercapto-1-(3-methyl-1,2,4-oxadiazol-5-yl)-ethylcarbamic acid tert-butyl ester | 173152-66-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (R)-2-mercapto-1-(3-methyl-1,2,4-oxadiazol-5-yl)-ethylcarbamic acid tert-butyl ester
• 英文别名: (R)-2-mercapto-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethylcarbamic acid tert-butyl ester；[(1R)-2-mercapto-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-carbamic acid 1,1-dimethylethyl ester；tert-butyl N-[(1R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)-2-sulfanylethyl]carbamate
• CAS: 173152-66-4
• 化学式: C₁₀H₁₇N₃O₃S
• 分子量: 259.329
• InChiKey: JIUQXZPUUZFJPE-ZETCQYMHSA-N

物化性质

• 密度：
  1.192±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  78.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (R)-2-mercapto-1-(3-methyl-1,2,4-oxadiazol-5-yl)-ethylcarbamic acid tert-butyl ester 在 劳森试剂 、 吗啉 、 氟化铵 、 四(三苯基膦)钯 、 1,2-二氯乙烷 、 三乙胺 、 三苯基膦 、 三氟乙酸 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 反应 23.5h， 生成 (7R,13R)-4-bromo-1-hydroxy-3-methoxy-13-(3-methyl-1,2,4-oxadiazol-5-yl)-7-phenyl-11-thioxo-9,10,11,12,13,14-hexahydro-16H-6-oxa-15-thia-9,12-diazabenzocyclotetradecene-5,8-dione
  参考文献：
  名称：

  基于双环Dilactam-内酯支架的Cyclothialidine家族的新的DNA促旋酶抑制剂亚类。合成与抗菌性能

  摘要：

  对于发现能够克服细菌对临床使用药物的耐药性的新型抗菌剂而言，DNA回旋酶抑制剂环噻啶已被证明是有价值的先导结构。先前已报道在其12-14元环中含有硫酰胺官能团的双环内酯衍生物对革兰氏阳性细菌表现出有效的抗菌活性。然而，仅对于带有亲水性取代基的衍生物证明了中等的体内功效，发现该衍生物对药物动力学具有有利的影响，并减少了代谢降解，特别是葡萄糖醛酸化。将一个额外的酰胺单元掺入环噻啶类似物的14元单内酰胺-内酯支架中，提供了一种新的固有的极性更高的DNA促旋酶抑制剂“双内酰胺”亚类。

  DOI：

  10.1021/jm1014023
• 作为产物：
  描述：

  N,N'-双(叔丁氧羰基)-L-胱氨酸 在 羟吡啶酮 、 三丁基膦 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 2,2,2-三氟乙醇 、 水 、 甲苯 为溶剂， 反应 22.0h， 生成 (R)-2-mercapto-1-(3-methyl-1,2,4-oxadiazol-5-yl)-ethylcarbamic acid tert-butyl ester
  参考文献：
  名称：

  New Antibacterial Agents Derived from the DNA Gyrase Inhibitor Cyclothialidine

  摘要：

  Cyclothialidine (1, Ro 09-1437) is a potent DNA gyrase inhibitor that was isolated from Streptomyces filipinensis NR0484 and is a member of a new family of natural products. It acts by competitively inhibiting the ATPase activity exerted by the B subunit of DNA gyrase but barely exhibits any growth inhibitory activity against intact bacterial cells, presumably due to insufficient permeation of the cytoplasmic membrane. To explore the antibacterial potential of 1, we developed a flexible synthetic route allowing for the systematic modification of its structure. From a first set of analogues, structure-activity relationships (SAR) were established for different substitution patterns, and the 14-hydroxylated, bicyclic core (X) of 1 seemed to be the structural prerequisite for DNA gyrase inhibitory activity. The variation of the lactone ring size, however, revealed that activity can be found among 11- to 16-membered lactones, and even seco-analogues were shown to maintain some enzyme inhibitory properties, thereby reducing the minimal structural requirements to a rather simple, hydroxylated benzyl sulfide (XI). On the basis of these "minimal structures" a modification program afforded a number of inhibitors that showed in vitro activity against Gram-positive bacteria. The best activities were displayed by 14-membered lactones, and representatives of this subclass exhibit excellent and broad in vitro antibacterial activity against Gram-positive pathogens, including Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, and overcome resistance against clinically used drugs. By improving the pharmacokinetic properties of the most active compounds (94, 97), in particular by lowering their lipophilic properties, we were able to identify congeners of cyclothialidine (1) that showed efficacy in vivo.

  DOI：

  10.1021/jm0310232

文献信息

• Mono- and bicyclic DNA gyrase inhibitors
  申请人：Hoffmann-La Roche Inc.

  公开号：US05589473A1

  公开（公告）日：1996-12-31

  The present invention relates to a compound of the formula ##STR1## wherein X.sup.1, R.sup.1, R.sup.2, OP, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.0 are as described herein, and their pharmaceutically acceptable salts thereof carrying an acidic and/or basic substituent. The compound of formula I as well as their pharmaceutically acceptable salts inhibit DNA gyrase activity in bacteria and possess antibiotic, especially antibacterial activity against microorganisms and can be used in the control or prevention of infectious diseases.

  本发明涉及一种具有以下结构的化合物##STR1##其中X.sup.1、R.sup.1、R.sup.2、OP、R.sup.3、R.sup.4、R.sup.5、R.sup.6和R.sup.0如本文所述，并且它们的药学上可接受的盐携带有酸性和/或碱性取代基。公式I的化合物以及它们的药学上可接受的盐抑制细菌中DNA旋转酶活性，并具有抗生素特别是抗菌活性，可用于控制或预防传染病。
• [EN] SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4)<br/>[FR] COMPOSES SULFAMIDES MODULANT L'ACTIVITE DES RECEPTEURS DES CHIMIOKINES (CCR4)
  申请人：ASTRAZENECA AB

  公开号：WO2004108692A1

  公开（公告）日：2004-12-16

  The invention relates to sulphonamide compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明涉及磺胺化合物、用于其制备的工艺和中间体、含有它们的药物组合物以及它们在治疗中的用途。
• Sulphonamide compounds that modulate chemokine receptor activity (ccr4)
  申请人：Harrison Richard

  公开号：US20060122195A1

  公开（公告）日：2006-06-08

  The invention relates to sulphonamide compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

  该发明涉及磺酰胺化合物、其制备过程和中间体、包含它们的制药组合物以及它们在治疗中的应用。
• Mono or bicyclic DNA gyrase inhibitors
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0675122A2

  公开（公告）日：1995-10-04

  The present invention relates to mono- or bicyclic compounds of the general formula wherein X1is -S- or -SO-; R1is hydrogen, halogen or lower alkyl, optionally substituted by halogen ; R2is hydrogen, hydroxy, amino, lower alkylamino, di-lower alkylamino, optionally substituted lower alkoxy or a group -OP; OPis an easily hydrolyzable group; R3is hydrogen, hydroxy, lower alkyl, halogen or a group -OP; R4is halogen, hydroxy or a group -OP; R5is hydrogen, cyano, optionally substituted esterified carboxy or optionally substituted amidated (thio)carboxy, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted heterocyclyl; R6is -NR7-A, -N=B or optionally substituted heterocyclyl, in which R7 is hydrogen or lower alkyl, A is optionally substituted iminoyl, optionally substituted (thio)acyl, optionally substituted esterified carboxy, optionally substituted amidated (thio)carboxy or optionally substituted heterocyclyl and B is optionally substituted alkylidene; R0is cyano, optionally substituted esterified carboxy or optionally substituted heterocyclyl, or wherein R0 and R6taken together represent a group         -CO-O-Q-X2-N(R7)-, wherein R7is as above, and X2is (thio)carbonyl or heterocyclyl; Qis -CH(R8)- or -CH(R8)-W-; R8is hydrogen or optionally substituted lower alkyl, and Wis optionally substituted mono-, di-, tri-, tetra- or pentamethylene, provided that when W is monomethylene X2 is other than (thio)carbonyl, and pharmaceutically acceptable salts of the mono- or bicyclic compounds of formula I carrying an acidic and/or basic substituent. These compounds of formula I as well as their pharmaceutically acceptable salts inhibit DNA gyrase activity in bacteria and possess antibiotic, especially antibacterial activity against microorganisms and can be used in the control or prevention of infectious diseases.

  本发明涉及通式如下的单环或双环化合物 其中 X1是-S-或-SO-； R1是氢、卤素或低级烷基，任选被卤素取代； R2 是氢、羟基、氨基、低级烷基氨基、二低级烷基氨基、任选被取代的低级烷氧基或基团 -OP； OP 是易水解基团； R3 是氢、羟基、低级烷基、卤素或基团 -OP R4 是卤素、羟基或基团 -OP R5是氢、氰基、任选取代的酯化羧基或任选取代的酰胺化（硫代）羧基、任选取代的烷基、任选取代的烯基或任选取代的杂环基； R6是-NR7-A、-N=B或任选取代的杂环基，其中R7是氢或低级烷基，A是任选取代的亚氨基酰基、任选取代的（硫代）酰基、任选取代的酯化羧基、任选取代的酰胺化（硫代）羧基或任选取代的杂环基，B是任选取代的亚烷基； R0 是氰基、任选取代的酯化羧基或任选取代的杂环基，或其中 R0 和 R6 合在一起代表一个基团 -CO-O-Q-X2-N(R7)-、 其中 R7 如上，以及 X2 是（硫代）羰基或杂环基； Q是-CH(R8)-或-CH(R8)-W-； R8 是氢或任选取代的低级烷基，以及 Wis 任选取代的一亚甲基、二亚甲基、三亚甲基、四亚甲基或五亚甲基，但当 W 为一亚甲基时，X2 不是（硫代）羰基、 和 带有酸性和/或碱性取代基的式 I 单环或双环化合物的药学上可接受的盐。 这些式 I 化合物及其药学上可接受的盐类可抑制细菌中 DNA 回旋酶的活性，并具有抗生素活性，特别是对微生物的抗菌活性，可用于控制或预防传染性疾病。
• SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4)
  申请人：AstraZeneca AB

  公开号：EP1633729B1

  公开（公告）日：2008-07-30